Kinetics of CAR-T cells and immunological profile after tisagenlecleucel therapy

[1]  J. Briones,et al.  Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies , 2023, Frontiers in Immunology.

[2]  Jiali Cheng,et al.  Monitoring anti‐CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction , 2022, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[3]  L. Gil,et al.  Artificial intelligence and chimeric antigen receptor T-cell therapy , 2022, Acta Haematologica Polonica.

[4]  Qihang Sun,et al.  Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies , 2021, Journal of Experimental & Clinical Cancer Research.

[5]  Lei Li,et al.  Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation , 2021, Frontiers in Immunology.

[6]  L. Gil,et al.  CAR-T cell therapy – toxicity and its management , 2020 .

[7]  D. Maloney,et al.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. , 2019, Blood.

[8]  W. Han,et al.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy , 2018, Biomarker Research.

[9]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.